Press coverage about Stemline Therapeutics (NASDAQ:STML) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stemline Therapeutics earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.9498685719707 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Stemline Therapeutics (STML) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)
- Stemline Therapeutics Inc Stock Investors Are Betting, Not Investing (investorplace.com)
- Stemline Therapeutics (STML) Lowered to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Stemline Therapeutics Inc Forecasted to Earn Q1 2018 Earnings of ($0.72) Per Share (STML) (americanbankingnews.com)
- Stemline Therapeutics (STML) Cut to “Hold” at BidaskClub (americanbankingnews.com)
A number of analysts recently issued reports on STML shares. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Stemline Therapeutics in a report on Friday, February 2nd. BidaskClub raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Finally, ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $31.33.
Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.26). Stemline Therapeutics had a negative net margin of 4,689.63% and a negative return on equity of 94.70%. analysts predict that Stemline Therapeutics will post -2.43 earnings per share for the current year.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 14,040 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $13.93, for a total value of $195,577.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Ivan Bergstein sold 3,820 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $15.80, for a total value of $60,356.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 156,418 shares of company stock worth $2,628,131. Insiders own 16.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Stemline Therapeutics (STML) Earns Daily Media Impact Score of 0.07” was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3295129/stemline-therapeutics-stml-earns-daily-media-impact-score-of-0-07.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.